Compare 3M Company (MMM) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs Summit Therapeutics Inc — how do they compare? 3M Company trades at $159.96 (market cap $84.36B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: 3M Company is far larger — about 6.2× Summit Therapeutics Inc's market cap, and 3M Company pays a 1.91% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and Summit Therapeutics Inc for 16 Days on average.
| MMM | SMMT | |
|---|---|---|
Market Cap | $84.36B | $13.71B |
Volume | 2,325,301 | 6,173,057 |
Sector | Industrials | Health |
52-Week High | $183.79 | $26.38 |
52-Week Low | $141.10 | $12.43 |
Typical Hold Time | 169 Days | 16 Days |
Enterprise Value | $93.58B | $13.04B |
Dividend Yield | 1.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $163.57, up 0.89% today, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.40, exceeding expectations, and maintains a net income margin of 11.9%. Analyst consensus is mixed with a $191 price target, while news highlights operational progress and litigation management.
Outlook is cautiously optimistic given earnings momentum and raised guidance, but risks include high debt, weak consumer demand, and technical bearishness. The stock offers potential upside to analyst targets if margin gains and industrial strength persist amid cost pressures.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
